WA
EW icon

WestEnd Advisors’s Edwards Lifesciences EW Stock Holding History

WestEnd Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54K Buy
17
+1
+6% +$84 ﹤0.01% 219
2026
Q1 		$1.28K Hold
16
– – ﹤0.01% 203
2025
Q4 		$1.36K Sell
16
-2
-11% -$164 ﹤0.01% 201
2025
Q3 		$1.4K Sell
18
-7
-28% -$547 ﹤0.01% 193
2025
Q2 		$1.96K Buy
25
+3
+14% +$224 ﹤0.01% 150
2025
Q1 		$1.59K Buy
22
+14
+175% +$1K ﹤0.01% 169
2024
Q4 		$592 Buy
8
+1
+14% +$70 ﹤0.01% 160
2024
Q3 		$462 Sell
7
-1
-13% -$73 ﹤0.01% 181
2024
Q2 		$739 Sell
8
-2
-20% -$177 ﹤0.01% 136
2024
Q1 		$956 Buy
10
+1
+11% +$84 ﹤0.01% 117
2023
Q4 		$686 Buy
9
+1
+13% +$70 ﹤0.01% 133
2023
Q3 		$554 Buy
+8
New +$643 ﹤0.01% 143
2023
Q1 		– Sell
-7
Closed -$550 – 133
2022
Q4 		$522 Sell
7
-1
-13% -$77 ﹤0.01% 143
2022
Q3 		$1K Hold
8
– – ﹤0.01% 108
2022
Q2 		$760 Buy
+8
New +$828 ﹤0.01% 121
2022
Q1 		– Sell
-5
Closed -$561 – 126
2021
Q4 		$647 Buy
+5
New +$583 ﹤0.01% 141
2021
Q3 		– Hold
0
– – – 137
2021
Q2 		– Hold
0
– – – 139

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

WestEnd Advisors's EW Position: Q2 2026 in Review

WestEnd Advisors increased its Edwards Lifesciences (EW) stake by 6.3% in Q2 2026, buying an estimated $84 and bringing the position to 17 shares worth $1.54K. The position accounts for ﹤0.01% of the portfolio, ranked #219.

WestEnd Advisors first reported a position in EW in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.96K in Q2 2025. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • WestEnd Advisors held 17 shares of Edwards Lifesciences worth $1.54K as of Q2 2026.
  • WestEnd Advisors bought 1 Edwards Lifesciences share in Q2 2026, an estimated $84.
  • Edwards Lifesciences made up ﹤0.01% of WestEnd Advisors's portfolio in Q2 2026, its #219 holding.
  • WestEnd Advisors first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 16 quarters since.
  • WestEnd Advisors's Edwards Lifesciences position peaked at $1.96K in Q2 2025.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on WestEnd Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.